Former Novartis Pharma Co., Ltd. Chairman Masao Torii appointed as Strategic Advisor for Life Science AI Business

2021.09.01 Press release

--To the press -

Former Novartis Pharma Co., Ltd. Chairman Masao Torii appointed as Strategic Advisor for Life Science AI Business

FRONTEO Inc.
Masahiro Morimoto, President and CEO
2-12-23 Konan, Minato-ku, Tokyo
(Code number: 2158 TSE Mothers)

 FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereafter FRONTEO) has been a member of the company's advisory board, and Torii, who has long held a key position in the pharmaceutical industry as a strategic advisor in the life science AI business. We announce that Mr. Masao has been appointed.

 

 Mr. Torii has been working for a foreign-affiliated pharmaceutical company for about 50 years, and has served as president of a Japanese corporation for a total of 4 years at four companies. He has a wealth of experience and achievements in the pharmaceutical industry, including serving as Vice Chairman. Since September 28, he has been Chairman of the Board of Novartis Pharma Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Leo Lee), but has recently retired on August 2020, 9.

 

 FRONTEO aims to expand the life science AI business and maximize its value by receiving advice from Mr. Torii on new business strategies in the field of AI drug discovery and research and development, promotion, and global expansion of language-based AI medical devices. increase.

 

■ Biography: Masao Torii
Born in Yokohama. After enrolling in the German language department of the Faculty of Foreign Studies, Sophia University in 1966, transferred to the Faculty of Business Administration of Loyola College, Maryland, USA in 1969, and graduated in 1971.Joined Nippon Roche in the same year. He has been responsible for corporate planning, sales and marketing for 1983 years, including being seconded to F Hoffmann La Roche in the United States and Switzerland from 1987 to 21.After that, he served as the top of four Japanese corporations of major foreign-affiliated pharmaceutical companies for 28 years.We practice challenging steering in a global organization to build and maintain a strong relationship of trust with overseas headquarters and at the same time provide maximum value to Japanese customers.
In 1993, he became president of the Japanese subsidiary of Rhone Poulenc Roller (France). 1995 President of Schering-Plough (USA) Japan.Acquired and integrated the Japanese subsidiary of Organon (Netherlands) during the term of office. In 2010, he concurrently served as President of Boehringer Ingelheim (Germany) Japan, and later President of SSP Co. Ltd., a commercial pharmaceutical manufacturer that was acquired and integrated. President of Novartis Holding Japan in 10, Chairman of Novartis Pharma Co., Ltd. in 2016, retired in August 2020. President of Sophia University Alumni Association since 2021.

Book: "Boss serve his subordinates!A New Era of Leadership Theory ”(Magazine House, 2009)
   "Ibaru's boss will end soon" (President, 2016)


■ About FRONTEO URL:https://www.fronteo.com/
FRONTEO uses the in-house developed AI engine "KIBIT" and "concept encoder" specializing in natural language processing to extract meaningful and important information from a huge amount of text data to support corporate business. A data analysis company. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support international litigation of companies. Has been deployed.Based on the AI ​​technology cultivated in the legal tech business, we expanded the business field to the life science field, business intelligence field, and economic security from 8, and by using AI to "turn text data into knowledge" , Drug discovery support, dementia diagnosis support, financial / human resources / sales support, etc., contributing to solving various corporate issues. Listed on TSE Mothers on June 2014, 2007. January 6 Obtained a first-class medical device manufacturing and sales license (permit number: 26B2021X1).The capital is 13 thousand yen (as of March 1, 10350).

* FRONTEO, conceptencoder, and KIBIT are registered trademarks of FRONTEO in Japan.

<Contact information for the press>

Public Relations Officer, FRONTEO Inc. Segawa

Email: pr_contact@fronteo.com

 

<Inquiries about Life Science AI Business>

FRONTEO Inc. Life Science AI Business Headquarters

https://lifescience.fronteo.com/contact

ja 日本語
Machine Translation by Google. : close x